{"id":"paroxetine-ir","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Headache"},{"rate":"10-20","effect":"Sexual dysfunction"},{"rate":"10-15","effect":"Insomnia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Sweating"}]},"_chembl":{"chemblId":"CHEMBL6067650","moleculeType":"Small molecule","molecularWeight":"749.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter protein, preventing the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing neurotransmission and improving mood regulation. The IR (immediate-release) formulation allows rapid absorption and onset of action compared to extended-release formulations.","oneSentence":"Paroxetine selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:38.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Panic disorder"},{"name":"Obsessive-compulsive disorder"},{"name":"Post-traumatic stress disorder"},{"name":"Social anxiety disorder"}]},"trialDetails":[{"nctId":"NCT04310579","phase":"PHASE1","title":"Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-06-15","conditions":"Hypercapnia, Ventilatory Depression","enrollment":55},{"nctId":"NCT05730062","phase":"PHASE1","title":"Influence of Oxycodone on Individuals Taking an SSRI","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-03-15","conditions":"Opioid Induced Respiratory Depression, Depressive Disorder, Anxiety Disorders","enrollment":55},{"nctId":"NCT03329573","phase":"PHASE1","title":"Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-05-30","conditions":"Anxiety Disorders","enrollment":85},{"nctId":"NCT01000857","phase":"PHASE1","title":"Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-05","conditions":"Depressive Disorder","enrollment":26},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT01838681","phase":"PHASE3","title":"Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-06","conditions":"Major Depressive Disorder","enrollment":1986},{"nctId":"NCT00866294","phase":"PHASE3","title":"Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04","conditions":"Depressive Disorder","enrollment":416},{"nctId":"NCT00368303","phase":"PHASE3","title":"A Local Register Study For Major Depression Of Paroxetine Controlled Release","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12","conditions":"Depressive Disorder, Major, Major Depressive Disorder (MDD)","enrollment":362}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Paroxetine CR"],"phase":"phase_3","status":"active","brandName":"Paroxetine IR","genericName":"Paroxetine IR","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paroxetine selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}